Fact-check: an emergency physician's top five GLP-1 problems

What the video covers

An emergency physician lists, in his order of frequency, the GLP-1-related presentations he sees: nausea and vomiting at initiation and dose increases; dehydration that can progress to acute kidney injury, explained through plasma volume and creatinine; starvation ketosis in people with prolonged low intake; muscle loss, which he attributes mainly to patients who are not strength training or eating enough protein; and depressed mood in a sustained caloric deficit. Gastroparesis is an honourable mention. He opens by saying none of it is medical advice.

What it gets right

The first two items are label warnings, not anecdotes. Both the Wegovy and Zepbound labels warn that gastrointestinal adverse reactions can cause dehydration and acute kidney injury, and advise monitoring renal function in patients with severe reactions. The physiology he gives for that chain is correct and clearly told. Nausea is the most common adverse reaction in every pivotal trial: 44 percent on Wegovy 2.4 mg in the pooled label data and 74 percent for any gastrointestinal event in STEP 1 (PubMed 33567185). Gastroparesis, or severe delayed gastric emptying, is now named in the labels, with advice against use in people with severe gastroparesis. His point that diabetes itself causes gastroparesis, which muddies the research, is fair.

Starvation ketosis is real, and the labels note diabetic ketoacidosis reports in people with type 2 diabetes when insulin was reduced too quickly. His muscle-loss advice, resistance training and adequate protein, is the standard recommendation.

What it leaves out or overstates

The ranking is by what walks through one emergency department, which selects for the sick and says nothing about how often each problem occurs per thousand users. The video does not give any rate, and viewers should not read "top five" as "most common overall".

Two sections rest on general evidence rather than GLP-1 data. The mood section cites the well-known link between sustained caloric deficit and low mood; the GLP-1 trials did not show an excess of depression, though the Wegovy label does advise monitoring for suicidal thoughts and behaviour after post-marketing reports. The muscle-loss section acknowledges "medium-quality evidence"; DXA substudies show roughly a quarter to a third of weight lost is lean mass, in line with other forms of weight loss, and the presenter's clinical impression that untrained patients fare worse is plausible but unmeasured.

The video does not mention pancreatitis, gallbladder disease or the thyroid C-cell warning, which are the label's other headline warnings, presumably because they are rare in his practice.

Where to go next

Dr. Nadolsky's video next in this playlist covers what to do about each GI effect, and the Stanford dietitian's webinar has the trial time-course. For protein targets during weight loss and a plateau check against the trial curves, use Weight Loss on GLP-1s. The GLP-1 Lab Guide explains creatinine and other labs worth watching. Compounded GLP-1s, including those FormBlends offers at formblends.com, are not FDA approved and carry the same physiological risks without the label's monitoring guidance attached.